Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat — VialBase Research

Summary

This preclinical study evaluated the effects of BPC-157 on medial collateral ligament (MCL) healing in a rat model. Both systemic (intraperitoneal) and local application of BPC-157 were tested, with assessments at multiple time points over 12 weeks. The study demonstrated significant improvement in ligament healing with both routes of administration.

Key Findings

• BPC-157 significantly improved biomechanical strength of healing MCL tissue
• Both intraperitoneal and local (topical) administration routes were effective
• Improved collagen fiber organization in healing ligament tissue
• Effects were dose-dependent and observed as early as one week post-injury
• Functional improvement persisted through the 12-week study endpoint

Methodology

Controlled animal study using 72 Wistar rats with surgically induced MCL transection. Animals randomized to BPC-157 (systemic or local) or saline control groups. Outcomes assessed via biomechanical testing (load-to-failure), histological analysis, and immunohistochemistry at 1, 2, 4, and 12 weeks post-injury.

Limitations

• Animal model (rat) — ligament biomechanics differ from human
• Single ligament type studied (MCL)
• No comparison with established treatments (e.g., PRP, surgical repair)
• Optimal dosing for humans cannot be directly extrapolated

Relevance to Content

Strong preclinical evidence for BPC-157 in ligament healing. Directly relevant to content targeting athletes, active individuals, or anyone recovering from ligament injuries. The dual-route efficacy (systemic and local) supports both injection and oral administration discussions.

See Also

• Parent compound: BPC-157